Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  356 نتائج ل ""Pyrroles""

فلترة النتائج

Subject : carcinoma, renal cell
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience.

  • Authors : Jaipuria J; Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.; Jain A

Subjects: Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/pathologyClear-cell metastatic renal cell carcinoma

  • Source: Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 493-500. Date of Electronic Publication: 2024 Jan 09.Publisher: Medknow Publications Country of Publication: India NLM ID: 0112040 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.

  • Authors : Ness DB; Department of Medicine and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Section of Clinical Pharmacology, Lebanon, New Hampshire, USA.; Pooler DB

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/pathology

  • Source: Cancer medicine [Cancer Med] 2023 Jun; Vol. 12 (12), pp. 13100-13110. Date of Electronic Publication: 2023 May 06.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Editorial & Opinion

Vascular density and expression of vascular endothelial growth factor and angiopoietin-1 using immunofluorescence technique in patients with metastatic renal cell carcinoma treated with first-line sunitinib.

  • Authors : Kraljević M; Oncology Clinic, University Clinical Hospital Mostar, 88 000 Mostar, Bosnia and Herzegovina.; Marijanović I

Subjects: Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/pathology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use

  • Source: Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Jan-Mar; Vol. 19 (2), pp. 520-521.Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print Cited Medium: Internet ISSN: 1998-4138

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.

  • Authors : Amaro F; Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.; UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology

  • Source: International journal of molecular sciences [Int J Mol Sci] 2022 Aug 31; Vol. 23 (17). Date of Electronic Publication: 2022 Aug 31.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.

  • Authors : Welsh SJ; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/diagnostic imaging ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy

  • Source: BJU international [BJU Int] 2022 Aug; Vol. 130 (2), pp. 244-253. Date of Electronic Publication: 2021 Nov 02.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.

  • Authors : Tullemans BME; Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands.; Brouns SLN

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/pathology

  • Source: BMC cancer [BMC Cancer] 2022 Jun 13; Vol. 22 (1), pp. 653. Date of Electronic Publication: 2022 Jun 13.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.

  • Authors : Rihacek M; Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic.; Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology

  • Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Jun 07; Vol. 29 (6), pp. 4138-4147. Date of Electronic Publication: 2022 Jun 07.Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.

  • Authors : Ohba K; Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Miyata Y

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy ; Indoles/Indoles/Indoles/*therapeutic use

  • Source: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2018 Jun; Vol. 14 (3), pp. 153-158. Date of Electronic Publication: 2018 Jan 31.Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.

  • Authors : Crumbaker M; Royal North Shore Hospital, NSW, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, NSW, Australia.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy ; Indoles/Indoles/Indoles/*therapeutic use

  • Source: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2018 Apr; Vol. 14 (2), pp. e45-e49. Date of Electronic Publication: 2017 Apr 21.Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.

  • Authors : Cabel L; Department of Medical Oncology, Cochin Hospital, AP-HP, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.; Paris Descartes University, CARPEM, Paris, France.

Subjects: Drug Monitoring*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*blood ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

  • Source: Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2018 Feb; Vol. 32 (1), pp. 98-107. Date of Electronic Publication: 2017 Nov 10.Publisher: Blackwell Science Country of Publication: England NLM ID: 8710411 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  356 نتائج ل ""Pyrroles""